Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer
US11357862B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 11, 2017 |
| Grant date | Jun 14, 2022 |
| Priority date | — |
| Expiry date | Nov 13, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K9/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8 is disclosed. The targeting peptide may be conjugated to a component selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent. Also disclosed are a kit for imaging and detecting the presence of prostate cancer cells in vivo or in vitro, and a composition for treating prostate cancer, inhibiting prostate cancer cell growth, inducing prostate cancer cell cytotoxicity, and/or increasing the survival rate in a prostate cancer patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.